156 related articles for article (PubMed ID: 19587164)
1. Sclerostin in mineralized matrices and van Buchem disease.
van Bezooijen RL; Bronckers AL; Gortzak RA; Hogendoorn PC; van der Wee-Pals L; Balemans W; Oostenbroek HJ; Van Hul W; Hamersma H; Dikkers FG; Hamdy NA; Papapoulos SE; Löwik CW
J Dent Res; 2009 Jun; 88(6):569-74. PubMed ID: 19587164
[TBL] [Abstract][Full Text] [Related]
2. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro.
Jäger A; Götz W; Lossdörfer S; Rath-Deschner B
J Periodontal Res; 2010 Apr; 45(2):246-54. PubMed ID: 19778325
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin expression in bone tumours and tumour-like lesions.
Inagaki Y; Hookway ES; Kashima TG; Munemoto M; Tanaka Y; Hassan AB; Oppermann U; Athanasou NA
Histopathology; 2016 Sep; 69(3):470-8. PubMed ID: 26896083
[TBL] [Abstract][Full Text] [Related]
5. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice.
Thompson ML; Jimenez-Andrade JM; Mantyh PW
J Histochem Cytochem; 2016 Mar; 64(3):179-89. PubMed ID: 26701970
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin expression and functions beyond the osteocyte.
Weivoda MM; Youssef SJ; Oursler MJ
Bone; 2017 Mar; 96():45-50. PubMed ID: 27888056
[TBL] [Abstract][Full Text] [Related]
8. Isolation and Functional Analysis of an Immortalized Murine Cementocyte Cell Line, IDG-CM6.
Zhao N; Nociti FH; Duan P; Prideaux M; Zhao H; Foster BL; Somerman MJ; Bonewald LF
J Bone Miner Res; 2016 Feb; 31(2):430-442. PubMed ID: 26274352
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin: current knowledge and future perspectives.
Moester MJ; Papapoulos SE; Löwik CW; van Bezooijen RL
Calcif Tissue Int; 2010 Aug; 87(2):99-107. PubMed ID: 20473488
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin, an osteocytes-derived bone-forming inhibitor.
Włodarski KH; Galus R; Brodzikowska A; Włodarski PK
Pol Orthop Traumatol; 2013 Jul; 78():151-4. PubMed ID: 23820854
[TBL] [Abstract][Full Text] [Related]
11. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
van Bezooijen RL; Papapoulos SE; Löwik CW
J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
[TBL] [Abstract][Full Text] [Related]
13. Serum Dickkopf 1 levels in sclerostin deficiency.
van Lierop AH; Moester MJ; Hamdy NA; Papapoulos SE
J Clin Endocrinol Metab; 2014 Feb; 99(2):E252-6. PubMed ID: 24302746
[TBL] [Abstract][Full Text] [Related]
14. The Cementocyte-An Osteocyte Relative?
Zhao N; Foster BL; Bonewald LF
J Dent Res; 2016 Jul; 95(7):734-41. PubMed ID: 27029548
[TBL] [Abstract][Full Text] [Related]
15. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
16. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis.
Appel H; Ruiz-Heiland G; Listing J; Zwerina J; Herrmann M; Mueller R; Haibel H; Baraliakos X; Hempfing A; Rudwaleit M; Sieper J; Schett G
Arthritis Rheum; 2009 Nov; 60(11):3257-62. PubMed ID: 19877044
[TBL] [Abstract][Full Text] [Related]
17. Human bone chips release of sclerostin and FGF-23 into the culture medium: an in vitro pilot study.
Brolese E; Buser D; Kuchler U; Schaller B; Gruber R
Clin Oral Implants Res; 2015 Oct; 26(10):1211-4. PubMed ID: 24888411
[TBL] [Abstract][Full Text] [Related]
18. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
Sebastian A; Loots GG
Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
[TBL] [Abstract][Full Text] [Related]
19. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
20. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
Bellido T; Ali AA; Gubrij I; Plotkin LI; Fu Q; O'Brien CA; Manolagas SC; Jilka RL
Endocrinology; 2005 Nov; 146(11):4577-83. PubMed ID: 16081646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
